key: cord-1051670-u1bh9l1e
authors: Abumayyaleh, Mohammad; Núñez Gil, Iván J.; El-Battrawy, Ibrahim; Estrada, Vicente; Becerra-Muñoz, Víctor Manuel; Aparisi, Alvaro; Fernández-Rozas, Inmaculada; Feltes, Gisela; Arroyo-Espliguero, Ramón; Trabattoni, Daniela; López-País, Javier; Pepe, Martino; Romero, Rodolfo; García, Diego Raúl Villavicencio; Biole, Carloalberto; Astrua, Thamar Capel; Eid, Charbel Maroun; Alfonso, Emilio; Fernandez-Presa, Lucia; Espejo, Carolina; Buonsenso, Danilo; Raposeiras, Sergio; Fernández, Cristina; Macaya, Carlos; Akin, Ibrahim
title: Does There Exist an Obesity Paradox in COVID-19? Insights of the international HOPE-COVID-19-Registry
date: 2021-03-03
journal: Obes Res Clin Pract
DOI: 10.1016/j.orcp.2021.02.008
sha: 74958919c2779b3837deb003c25216ff96911e27
doc_id: 1051670
cord_uid: u1bh9l1e

BACKGROUND: Obesity has been described as a protective factor in cardiovascular and other diseases being expressed as ‘obesity paradox’. However, the impact of obesity on clinical outcomes including mortality in COVID-19 has been poorly systematically investigated until now. We aimed to compare clinical outcomes among COVID-19 patients divided into three groups according to the body mass index (BMI). METHODS: We retrospectively collected data up to May 31(st), 2020. 3635 patients were divided into three groups of BMI (<25 kg/m(2); n = 1110, 25-30 kg/m(2); n = 1464, and >30 kg/m(2); n = 1061). Demographic, in-hospital complications, and predictors for mortality, respiratory insufficiency, and sepsis were analyzed. RESULTS: The rate of respiratory insufficiency was more recorded in BMI 25-30 kg/m(2) as compared to BMI < 25 kg/m(2) (22.8% vs. 41.8%; p < 0.001), and in BMI > 30 kg/m(2) than BMI < 25 kg/m(2), respectively (22.8% vs. 35.4%; p < 0.001). Sepsis was more observed in BMI 25-30 kg/m(2) and BMI > 30 kg/m(2) as compared to BMI < 25 kg/m(2), respectively (25.1% vs. 42.5%; p = 0.02) and (25.1% vs. 32.5%; p = 0.006). The mortality rate was higher in BMI 25-30 kg/m(2) and BMI > 30 kg/m(2) as compared to BMI < 25 kg/m(2), respectively (27.2% vs. 39.2%; p = 0.31) (27.2% vs. 33.5%; p = 0.004). In the Cox multivariate analysis for mortality, BMI < 25 kg/m(2) and BMI > 30 kg/m(2) did not impact the mortality rate (HR 1.15, 95% CI: 0.889-1.508; p = 0.27) (HR 1.15, 95% CI: 0.893-1.479; p = 0.27). In multivariate logistic regression analyses for respiratory insufficiency and sepsis, BMI < 25 kg/m(2) is determined as an independent predictor for reduction of respiratory insufficiency (OR 0.73, 95% CI: 0.538-1.004; p = 0.05). CONCLUSIONS: HOPE COVID-19-Registry revealed no evidence of obesity paradox in patients with COVID-19. However, Obesity was associated with a higher rate of respiratory insufficiency and sepsis but was not determined as an independent predictor for a high mortality.

Obesity has been described as a protective factor in cardiovascular and other diseases being expressed as 'obesity paradox'. However, the impact of obesity on clinical outcomes including mortality in COVID-19 has been poorly systematically investigated until now. We aimed to compare clinical outcomes among COVID-19 patients divided into three groups according to the body mass index (BMI).

We retrospectively collected data up to May 31 st , 2020. 3635 patients were divided into three groups of BMI (<25 kg/m 2 ; n=1110, 25-30 kg/m 2 ; n=1464, and >30 kg/m 2 ; n=1061).

Demographic, in-hospital complications, and predictors for mortality, respiratory insufficiency, and sepsis were analyzed.

The rate of respiratory insufficiency was more recorded in BMI The prevalence of obesity increases worldwide over the last decade which represents more health care challenges. It is associated with a high prevalence of diabetes mellitus type 2, fatty liver disease, hypertension, myocardial infarction, and several other cardiovascular diseases (1, 2) .

Obesity is identified as a predictor for the development of infections such as influenza A (H1N1) infection and community-acquired pneumonia (CAP) (3, 4) . Recently, a high prevalence of coronavirus disease 2019 (COVID-19) in obese patients was reported (5, 6) . It has been reported that the risk for a severe course of COVID-19 with intensive care unit (ICU) and requiring invasive mechanical ventilation is higher in COVID-19 with concomitant obesity than without (7) (8) (9) (10) (11) . On the other hand, the mortality rate in obesity is not higher as compared to non-obese patients in CVOID-19 (12) . However, data were based on a small number of patients and limited participating centers.

The obesity paradox in cancer, heart failure, and acute respiratory distress syndrome (ARDS) has been studied recently (13) (14) (15) . Obesity was associated with a lower mortality rate in patients with ARDS (13) . A chronic pro-inflammatory status in obesity may limit the worse effects of second inflammation due to sepsis or ventilator-induced lung injury (16) . Of note, patients with COVID-19 are suffering from ARDS (17) . If there is an obesity paradox in COVID-19, has not been yet studied.

This present study investigated the impact of BMI on in-hospital complications and the outcome of CVOID-19 e.g., respiratory insufficiency, sepsis, and mortality of the international HOPE-Registry.

HOPE-COVID-19 (Health Outcome predictive Evaluation for COVID-19, NCT04334291) is an international project (18, 19) . It is designed as a retrospective cohort registry without any financial support. Hospitalized COVID-19 patients were included. An online database was built and completed by each participating center (www.HopeProjectMD.com). We analyzed all included patients up to to May 31 st , 2020. We excluded 4503 patients due to a lack of data about body mass index (BMI). Additionally, 30 patients were excluded due to age <18, 

We described as primary end-point all-cause mortality, respiratory insufficiency, and sepsis.

Requiring Oxygen at admission including high nasal-canula, non-invasive ventilation, and invasive mechanical ventilation, heart failure, clinically relevant bleeding, and embolic events as secondary endpoints were also evaluated.

Descriptive and comparative analyses were presented. Categorical variables were performed as frequency rates and percentages, while continuous variables were presented as mean ± standard deviation if the distribution was normal, or median (interquartile range) if not. For group comparisons, the chi-square test was used for categorical variables. Comparative analysis of the quantitative variables was presented using the Mann-Whitney U test for nonparametric variables and the T-student test was used for parametric variables, as verified by the Kolmogorov-Smirnov test. Odds ratios (OR) with 95% confidence intervals (95% CI) were calculated in a multivariable logistic regression test for the determination of risk factors for endpoints. Hazard ratios (HR) and survival curves with 95% CI were calculated in the survival analysis by Cox regression and Kaplan-Meier method, respectively. P-value <0.05 was recognized as statistically significant. Statistical analysis was presented in two subgroups. The first subgroup consisted of patients with a BMI <25 kg/m 2 and BMI 25-30 kg/m 2 , while the second group consisted of patients with BMI <25 kg/m 2 and BMI >30 kg/m 2 . We analyzed all variables that were described recently with a high impact on outcomes (19). Predictors of mortality, respiratory insufficiency, and sepsis were identified J o u r n a l P r e -p r o o f by univariate analysis. Predictors with p < 0.05 were analyzed by the Cox or logistic multivariate regression. The multivariable Cox regression was used to investigate predictors of mortality, while multivariable logistic regression was used to investigate predictors of respiratory insufficiency and sepsis adjusting all significant variables: age, gender, ICU (intensive care unit) admission, BMI <25 kg/m 2 , BMI >30 kg/m2, previous medical history, and comorbidities such as arterial hypertension, dyslipidemia, diabetes mellitus (DM), renal insufficiency, heart-, cerebrovascular-, liver-, cancer disease, immunosuppression, home oxygen therapy, peripheral oxygen saturation (SpO2) <92%, Glasgow Coma scale (GCS), reduced blood pressure (Systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg), laboratory parameters, and radiological findings (unilateral and bilateral infiltrates).

Statistical analysis was showed with SPSS statistics version 27.

In HOPE-COVID-19-Registry, the data of 3635 consecutive hospitalized patients with COVID-19 were gathered. These patients were divided into three categories of BMI with a median age of 59 (18- 

Respiratory insufficiency was significantly more recorded with an increase of BMI ( figure 3 .

The present study shows patient characteristics at baseline, in-hospital complications, and mortality rate in patients with COVID-19 according to BMI. The main findings of the study are (1) The increase of BMI was associated with a higher incidence of respiratory insufficiency and sepsis; (2) BMI <25 kg/m 2 is determined as an independent predictor for J o u r n a l P r e -p r o o f reduction of respiratory insufficiency; (3) The increase of BMI did not impact the mortality rate in patients with COVID-19.

The HOPE-COVID-19-Registry shows more comorbidities in patients with BMI >30 kg/m 2 such as arterial hypertension, dyslipidemia, diabetes mellitus, lung-, and heart disease.

Because of these comorbidities, obese patients may develop more in-hospitals complications for example respiratory insufficiency, heart failure, acute kidney injury, pneumonia, and sepsis. Of note, BMI <25 kg/m 2 is determined as an independent predictor for reduction of respiratory insufficiency in COVID-19. In this context, respiratory insufficiency with acute respiratory distress syndrome (ARDS) was recently more observed in patients with severe obesity BMI >35 kg/m 2 (21) . In addition, the rate of viral pneumonia was higher in obesity as compared to non-obesity (22, 23) . Obesity seems to decrease chest-wall elastance, which leads to lower total respiratory compliance with a reduction of expiratory reserve volume and a higher susceptibility for infection (24) . Even more, obesity is associated with impaired total lung capacity and increased airway resistance as well as ventilation-perfusion mismatch (25) .

In addition, adipose tissue may be vulnerable to more infection due to more expression of angiotensin-converting enzyme 2 with directly binding with SARS-CoV-2 (26). These difficulties are a challenge for physicians regarding the management of COVID-19 with concomitant obesity.

Our data presented more need for proning in patients with BMI 25-30 kg/m 2 and BMI >30 kg/m 2 due to more respiratory insufficiency in these groups. In addition, ECMO was more used in patients with a BMI >30 kg/m 2 . Concerning the management of ARDS patients, proning reduced the in-hospital-mortality and showed better effects on outcomes (27). In this context, the alveolar volume distributions improved more in patients with BMI >30 kg/m 2 as J o u r n a l P r e -p r o o f compared to BMI < 25 due to a greater reduction of alveolar volume variance when turning from supine to prone (28). In 362 patients with BMI >30 kg/m 2 who received ECMO, BMI >30 kg/m 2 was not determined as an independent predictor for the high in-hospital mortality (29).

In the Cox multivariate analysis, BMI >30 kg/m 2 is not determined as an independent predictor for a high mortality rate. In the first report of the international HOPE-registry in 1021 patients, obesity was an independent predictor for mortality particularly in patients <70 years (18) . However, in the present analysis, we investigated predictors of mortality in 3335 patients across all age categories. Another study showed that obesity was associated with a high rate of in-hospital mortality in patients with COVID-19 (21) . This cohort consisted of 162 patients with BMI >25 kg/m 2 , also the statement is not based on enough evidence in patients with COVID-19. However, the risk of death was high in severe obesity with BMI >40 kg/m 2 (30) . In another analysis in 331 patients with COVID-19, ICU admission was more revealed in patients with BMI >30 kg/m 2 , but the obesity was not associated with a high mortality rate (12) . Additionally, the obesity paradox in COVID-19 was also reported (31).

Summarizing, normal BMI <25 kg/m 2 is determined as an independent predictor for reduction of respiratory insufficiency, but not for mortality or sepsis. BMI 25-30 kg/m 2 and BMI >30 kg/m 2 were not associated with a high mortality, respiratory insufficiency, or sepsis rate in patients with COVID-19.

The study was approved by the central Ethics Committee and, when needed, in all involved centers. 

Obesity: global epidemiology and pathogenesis

Associations of Chronic Inflammation

Severe Obesity With Mortality, Myocardial Infarction, Cancer, and Chronic Pulmonary Disease

Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis

A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women

Obesity a risk factor for increased COVID19 prevalence, severity and lethality (Review)

The Association of Obesity, Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients

High in hospitalised COVID-19 patients? Results from a single Italian centre

BMI is Associated with Coronavirus Disease 2019 Intensive Care Unit Admission in African Americans

Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data

Obesity and the Risk of Intubation or Death in Patients With Coronavirus Disease

The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort

Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis

Obesity in heart failure: is it time to rethink the paradox?

The Obesity Paradox in Cancer: a Review

Does Coronavirus Disease 2019 Disprove the Obesity Paradox in

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design

Severe obesity, increasing age and male sex are independently associated with worse inhospital outcomes, and higher in-hospital mortality

Predicting COVID-19 Using Retrospective Data: Impact of Obesity on Outcomes of Adult Patients With Viral Pneumonia

Association between

Body Mass Index and Risk of COVID-19: A Nationwide Case-Control Study in South Korea

Perioperative management of obese patients

Altered respiratory physiology in obesity

BMI <25 vs. BMI 25-30; 2, BMI <25 vs

Immunosuppressive therapy for psoriasis arthritis, lung transplantation, kidney transplantation or systemic lupus erythematosus; oncological disease such as mamma-ca, prostate-ca, myelodysplastic syndrome or gammopathy, glucocorticoid therapy caused by COPD, dialysis, HIV or hepatitis; Ω, acetylsalicylic acid; µ, angiotensin-converting enzyme/angiotensin receptor blocker

Systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg. Ø Glasgow coma scale. ∂ C-reactive Protein. ∞ High sensitive Troponin I (cardiac injury